The Downregulation of Prognosis- and Immune Infiltration-Related Gene CYFIP2 Serves as a Novel Target in ccRCC

References

• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3(1):17009. doi:10.1038/nrdp.2017.9
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–1564. doi:10.1126/science.1203543
   PubMed Web of Science ®Google Scholar
• Yin L, Li W, Xu A, et al. SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-twist1 pathway. EBioMedicine. 2020;51:102596. doi:10.1016/j.ebiom.2019.12.005
   PubMed Web of Science ®Google Scholar
• Gilyazova IR, Klimentova EA, Bulygin KV, et al. MicroRNA-200 family expression analysis in metastatic clear cell renal cell carcinoma patients. Cancer Gene Ther. 2020;27(10–11):768–772. doi:10.1038/s41417-019-0149-z
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research, N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. doi:10.1038/nature12222
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442
   PubMed Web of Science ®Google Scholar
• Schenck A, Bardoni B, Moro A, Bagni C, Mandel JL. A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. Proc Natl Acad Sci USA. 2001;98(15):8844–8849. doi:10.1073/pnas.151231598
   PubMed Web of Science ®Google Scholar
• Abekhoukh S, Bardoni B. CYFIP family proteins between autism and intellectual disability: links with Fragile X syndrome. Front Cell Neurosci. 2014;8:81. doi:10.3389/fncel.2014.00081
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lee Y, Han K. Neuronal function and dysfunction of CYFIP2: from actin dynamics to early infantile epileptic encephalopathy. BMB Rep. 2019;52(5):304–311. doi:10.5483/BMBRep.2019.52.5.097
   PubMed Web of Science ®Google Scholar
• Tiwari SS, Mizuno K, Ghosh A, et al. Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss. Brain. 2016;139(Pt 10):2751–2765. doi:10.1093/brain/aww205
   PubMed Web of Science ®Google Scholar
• Nakashima M, Kato M, Aoto K, et al. De novo hotspot variants in CYFIP2 cause early-onset epileptic encephalopathy. Ann Neurol. 2018;83(4):794–806. doi:10.1002/ana.25208
   PubMed Web of Science ®Google Scholar
• Zweier M, Begemann A, McWalter K, et al. Spatially clustering de novo variants in CYFIP2, encoding the cytoplasmic FMRP interacting protein 2, cause intellectual disability and seizures. Eur J Hum Genet. 2019;27(5):747–759. doi:10.1038/s41431-018-0331-z
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kang H, Lee Y, et al. Smaller body size, early postnatal lethality, and cortical extracellular matrix-related gene expression changes of Cyfip2-null embryonic mice. Front Mol Neurosci. 2018;11:482. doi:10.3389/fnmol.2018.00482
   PubMed Web of Science ®Google Scholar
• Silva JM, Ezhkova E, Silva J, et al. Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell. 2009;137(6):1047–1061. doi:10.1016/j.cell.2009.04.013
   PubMed Web of Science ®Google Scholar
• Shi X, Chen X, Li WC, et al. Low expression of Cyfip1 may be a potential biomarker in nasopharyngeal carcinoma. Neoplasma. 2018;65(2):292–295. doi:10.4149/neo_2018_170318N194
   PubMed Web of Science ®Google Scholar
• Dziunycz PJ, Neu J, Lefort K, et al. CYFIP1 is directly controlled by NOTCH1 and down-regulated in cutaneous squamous cell carcinoma. PLoS One. 2017;12(4):e0173000. doi:10.1371/journal.pone.0173000
   PubMed Web of Science ®Google Scholar
• Chang YS, Huang HD, Yeh KT, Chang JG. Identification of novel mutations in endometrial cancer patients by whole-exome sequencing. Int J Oncol. 2017;50(5):1778–1784. doi:10.3892/ijo.2017.3919
   PubMed Web of Science ®Google Scholar
• Shabani S, Khayer N, Motalebzadeh J, Majidi Zadeh T, Mahjoubi F. Characterization of pathways involved in colorectal cancer using real-time RT-PCR gene expression data. Gastroenterol Hepatol Bed Bench. 2021;14(2):123–131.
   PubMedGoogle Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Xiao W, Wang X, Wang T, Xing J. MiR-223-3p promotes cell proliferation and metastasis by downregulating SLC4A4 in clear cell renal cell carcinoma. Aging. 2019;11(2):615–633. doi:10.18632/aging.101763
   PubMedGoogle Scholar
• Yuan C, Xiong Z, Shi J, et al. Overexpression of PPT2 represses the clear cell renal cell carcinoma progression by reducing epithelial-to-mesenchymal transition. J Cancer. 2020;11(5):1151–1161. doi:10.7150/jca.36477
   PubMed Web of Science ®Google Scholar
• Xiao W, Wang X, Wang T, Xing J. Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma. Cancer Gene Ther. 2020;27(5):330–340. doi:10.1038/s41417-019-0107-9
   PubMed Web of Science ®Google Scholar
• Jiao S, Li N, Cai S, Guo H, Wen Y. Inhibition of CYFIP2 promotes gastric cancer cell proliferation and chemoresistance to 5-fluorouracil through activation of the Akt signaling pathway. Oncol Lett. 2017;13(4):2133–2140. doi:10.3892/ol.2017.5743
   PubMed Web of Science ®Google Scholar
• Jackson RS 2nd, Cho YJ, Stein S, Liang P. CYFIP2, a direct p53 target, is leptomycin-B sensitive. Cell Cycle. 2007;6(1):95–103. doi:10.4161/cc.6.1.3665
   PubMed Web of Science ®Google Scholar
• Liang YC, Wang JL, Wang HT, Liu H, Zhang HL, Liang YX. ADRM1 as a therapeutic target in hepatocellular carcinoma. Kaohsiung J Med Sci. 2020:37(1):47–54.
   PubMed Web of Science ®Google Scholar
• Lin PH, Tung YT, Chen HY, et al. Melatonin activates cell death programs for the suppression of uterine leiomyoma cell proliferation. J Pineal Res. 2020;68(1):e12620. doi:10.1111/jpi.12620
   PubMed Web of Science ®Google Scholar
• Karimzadeh MR, Pourdavoud P, Ehtesham N, et al. Regulation of DNA methylation machinery by epi-miRNAs in human cancer: emerging new targets in cancer therapy. Cancer Gene Ther. 2020;28(3):157–174.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen W, Yu F, et al. Long noncoding RNA HITTERS protects oral squamous cell carcinoma cells from endoplasmic reticulum stress-induced apoptosis via promoting MRE11-RAD50-NBS1 complex formation. Adv Sci. 2020;7(22):2002747. doi:10.1002/advs.202002747
   Web of Science ®Google Scholar
• Liu S, Cheng K, Zhang H, et al. Methylation status of the nanog promoter determines the switch between cancer cells and cancer stem cells. Adv Sci. 2020;7(5):1903035. doi:10.1002/advs.201903035
   Web of Science ®Google Scholar
• Li W, Huang K, Wen F, et al. LINC00184 silencing inhibits glycolysis and restores mitochondrial oxidative phosphorylation in esophageal cancer through demethylation of PTEN. EBioMedicine. 2019;44:298–310. doi:10.1016/j.ebiom.2019.05.055
   PubMed Web of Science ®Google Scholar
• Xiang S, Dauchy RT, Hoffman AE, et al. Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer. J Pineal Res. 2019;67(2):e12586. doi:10.1111/jpi.12586
   PubMed Web of Science ®Google Scholar
• Peng W, Huang W, Ge X, Xue L, Zhao W, Xue J. Type Igamma phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer. EBioMedicine. 2019;44:375–386. doi:10.1016/j.ebiom.2019.05.015
   PubMed Web of Science ®Google Scholar
• Linehan WM, Schmidt LS, Crooks DR, et al. The metabolic basis of kidney cancer. Cancer Discov. 2019;9(8):1006–1021. doi:10.1158/2159-8290.CD-18-1354
   PubMed Web of Science ®Google Scholar
• Xiao W, Wang X, Wang T, Chen B, Xing J. HAO2 inhibits malignancy of clear cell renal cell carcinoma by promoting lipid catabolic process. J Cell Physiol. 2019;234(12):23005–23016. doi:10.1002/jcp.28861
   PubMed Web of Science ®Google Scholar
• Xiao W, Wang C, Chen K, et al. MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2. EBioMedicine. 2020;51:102622. doi:10.1016/j.ebiom.2019.102622
   PubMed Web of Science ®Google Scholar
• Wettersten HI, Aboud OA, Lara PN Jr., Weiss RH. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017;13(7):410–419. doi:10.1038/nrneph.2017.59
   PubMed Web of Science ®Google Scholar
• Xiao W, Xiong Z, Xiong W, et al. Melatonin/PGC1A/UCP1 promotes tumor slimming and represses tumor progression by initiating autophagy and lipid browning. J Pineal Res. 2019;67(4):e12607. doi:10.1111/jpi.12607
   PubMed Web of Science ®Google Scholar
• Xiao W, Chen K, Zhang X. Pivotal biomarker expression and drug screening in advanced ccRCC. Clin Transl Med. 2020;10(2):e114. doi:10.1002/ctm2.114
   PubMed Web of Science ®Google Scholar
• Wen YC, Lin YW, Chu CY, et al. Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma. J Pineal Res. 2020;69(2):e12668. doi:10.1111/jpi.12668
   PubMed Web of Science ®Google Scholar
• Shen S, Wang JW, Zheng BH, et al. The lnc-CITED2-2:1 inhibits metastasis via inhibiting CITED2 and epithelial-mesenchymal transition in gallbladder cancer. Clin Transl Med. 2020;10(2):e116.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang M, Wen Y, et al. Biphasic regulation of mesenchymal genes controls fate switches during hematopoietic differentiation of human pluripotent stem cells. Adv Sci. 2020;7(20):2001019. doi:10.1002/advs.202001019
   Web of Science ®Google Scholar
• Agrawal B. New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota. Clin Transl Med. 2019;8(1):23. doi:10.1186/s40169-019-0241-x
   PubMed Web of Science ®Google Scholar
• Toulmonde M, Lucchesi C, Verbeke S, et al. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. EBioMedicine. 2020;62:103131. doi:10.1016/j.ebiom.2020.103131
   PubMed Web of Science ®Google Scholar
• Frohlich A, Sirokay J, Fietz S, et al. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. EBioMedicine. 2020;59:102962. doi:10.1016/j.ebiom.2020.102962
   PubMed Web of Science ®Google Scholar
• Mayne M, Moffatt T, Kong H, et al. CYFIP2 is highly abundant in CD4+ cells from multiple sclerosis patients and is involved in T cell adhesion. Eur J Immunol. 2004;34(4):1217–1227. doi:10.1002/eji.200324726
   PubMed Web of Science ®Google Scholar